An official website of the United States government
Home
Name
Vidaza
Alternate Names
496
5-Azacitidine
5-Azacytidine
Antibiotic U-18
Azacitidine
Azacytidine
Ladakamycin
Abbreviations
5-AC
5-AZA
5-AZAC
5-AZCR
AZA-CR
AZC
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
102816
Primary Site
Myelodysplastic syndromes
Histology
Myelomonocytic leukemia
Remarks
May 27, 2022 FDA approved Vidaza (azacitidine) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.
Clinical trials for MDS and AML. Antineoplastic agent; reduction in size or spread of neoplasm; improvement in hematologic parameters; bone marrow aspirate; antimetabloite; also differentiation inducing agent.
Clinical trials for MDS and AML. Antineoplastic agent; reduction in size or spread of neoplasm; improvement in hematologic parameters; bone marrow aspirate; antimetabloite; also differentiation inducing agent.
Coding
This drug should be coded
